Treatment with A1155463 reduced senescence markers in DM1 myoblasts (e.g., number of SA‐β‐galactosidase positive cells, P16 expression) as well as SASP expression (e.g., reduced levels of CSF3, CXCL1, CXCL8, CCL2, MMP‐1, and MMP‐3) [37]. This evidence concerns the gene CXCL8 and myotonic dystrophy type 1.